{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"39","value":"38.0"},{"groupId":"OG001","spread":"43","value":"103"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51","value":"47.9"},{"groupId":"OG001","spread":"40","value":"131"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"68"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51","value":"69.0"},{"groupId":"OG001","spread":"54","value":"189"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"title":"Steady State (Cycle 6-10)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"description":"Maximum Concentration (Cmax) of Tabalumab.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 milligram per square meter (mg/m\\^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG000","title":"100 mg Tabalumab+Dexamethasone+Bortezomib"},{"description":"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 mg/m\\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG001","title":"300 mg Tabalumab+Dexamethasone+Bortezomib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least 1 dose of study drug and evaluable PK data.","reportingStatus":"POSTED","timeFrame":"Cycle (C)1 Day (D)1: Predose, 3O minutes, 2 hours Postdose; C1 D4, 8, 11: Predose, (D11 only, 30 minutes Postdose); C2 and C6-C10 D1: Predose and immediately Postdose; C2 D 4, 8, 11: Anytime","title":"Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tabalumab","type":"SECONDARY","unitOfMeasure":"micrograms per milliliter"}